Science and Technology Grants

The Grassroots Arts Program, offered by The Arts Council of Wilmington & New Hanover, aims to support quality arts programs and the operation of arts organizations within New Hanover County, North Carolina. This initiative directly aligns with the mission of fostering a vibrant arts community by providing essential funding for both program and operating expenses. The program emphasizes accessibility and community engagement, ensuring that arts are available to a broad audience and contribute to the cultural enrichment of the region. The target beneficiaries of this grant include qualified arts organizations, community, civic, and municipal organizations, as well as educational institutions like colleges, universities, and libraries that conduct community-based arts programs. The impact goals are to strengthen existing arts infrastructure, promote arts learning and arts-in-education, and facilitate broader community involvement in the arts. By supporting these diverse entities, the program seeks to cultivate a thriving artistic landscape and enhance the quality of life for residents. Funding priorities include operating or programming support for arts organizations not already receiving state support, arts learning and arts-in-education programs conducted by qualified artists (such as artist residencies in schools or afterschool camps), and subgrants to community, civic, and municipal organizations for programs led by qualified artists. The program also has specific policies regarding tribal organizations, colleges, universities, and religious organizations, ensuring funds are used for community-based arts programs rather than internal or religious content. Expected outcomes include an increase in the number and quality of arts programs available to the community, enhanced arts education opportunities for various age groups, and strengthened operational capacity for local arts organizations. Measurable results will likely involve tracking the number of programs supported, the reach of those programs within the community, and the stability of recipient organizations. The grant awards, typically ranging from $500-$5000, are expected to support projects taking place between July 1, 2024, and June 15, 2025, further indicating a focus on immediate and tangible impact. The Arts Council of Wilmington & New Hanover's strategic priority is to invest in local arts and cultural initiatives that demonstrate community benefit and artistic merit. Their theory of change suggests that by providing direct financial support to qualified organizations and programs, they can stimulate artistic activity, encourage public participation, and ultimately contribute to the economic and social well-being of New Hanover County. The requirement for a dollar-for-dollar match also indicates a strategic approach to leverage community investment and ensure the sustainability of funded projects.

The "DoD Tick-Borne Disease, Therapeutic/Diagnostic Research Award" is a grant aimed at supporting the development of new treatments and diagnostic methods for tick-borne diseases, with a focus on improving patient care and quality of life for military service members, veterans, their families, and the general public.

The NSF Research Traineeship (NRT) Program seeks proposals that explore ways for graduate students in research-based masters and doctoral degree programs to develop the skills, knowledge, and competencies needed to pursue a range of science, technology, engineering, and mathematics (STEM) careers. This solicitation describes a pilot for a potential new track for the existingNRT Programthat will support research and education projects that will result in a new masters degree, certificate, or a track within an existing masters or Ph.D. program with high industry relevance in at least one focus area identified in this pilot. This will be accomplished through an effective partnership among: (a) a non-R1 Institution of Higher Education (IHE) (lead institution), (b) an non-lead IHE (an R1 or non-R1) that has either an ongoing or completed NRT program in at least one of the focus areas defined for this pilot (see below), and (c) two to three industry partners in the same focus area(s). The overall purpose is to train the STEM workforce in focus areas specified in this solicitation by stimulating collaborations among non-R1 institutions, institutions with existing or completed NRT projects, and industry partners.

The DoD Tick-Borne Disease, Idea Development Award is a grant aimed at funding innovative research that could significantly advance the understanding and treatment of Lyme disease and other tick-borne diseases, ultimately improving the lives of military personnel, veterans, their families, and the general public.

The US Geological Survey is offering a funding opportunity to a CESU partner for research on wild horse population demography and ecology throughout the Western USA. This research will be comprised of a combination of field-based data collection and research, and data analyses through modelling techniques. The National Academies of Science (NAS) conducted a science review of the Bureau of Land Management (BLM) wild horse and burro program in 2013. An outcome of this NAS review was a number of recommendations for new research, identification of data gaps, and knowledge needs. The aim is to fill some of those data needs with collaborative research conducted jointly by USGS and CESU partner.

The objectives of the proposed research effort include: Monitor and report performance of dredged material placed at beneficial use sites, specifically mine land reclamation and landfill cover sites. Factors to be monitored include, but are not limited to:a. Ecosystem recovery and functionalityb. Water qualityc. Landscape stabilityd. Vegetation growth Successful applicants should have expert knowledge of confined disposal facilities and beneficial use of dredged material. The applicant should also have a record that demonstrates applied research and monitoring experience with both topics. The candidates should have prior experience with monitoring beneficial use sites. The candidates will be required to prepare a Statement of Work and Work Plan regarding the research to be conducted. The candidate will also be required to submit three (3) quarterly status reports and one (1) annual report each year of the contract to provide updates on the work being conducted.

The US Geological Survey is offering a funding opportunity to a CESU partner for research on pollinators of northern Arizona throughout semi-arid grasslands that are utilized by bison. This research will be primarily comprised of field-based data collection prior to analyses of quantified biological data. The goal of this research is to examine pollinator communities, resources, and habitat quality in relation to areas of varying bison densities. Previous grazing exclusion experiments in this ecosystem revealed grazing-induced ecological changes that lead to altered grassland structure (i.e., plant species composition) and function (i.e., plant production, nutrient dynamics) (Musto 2023). However, no information has been collected on whether (and how) bison-induced changes to plant communities may affect the pollinator communities that utilize flowing plants as food resources and habitat.

Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) 2024 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 14, 2024. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates (Tables 2 and 3), a table that provides a very top level summary of proposal contents (Table 1), and the full text of the ROSES-2024 "Summary of Solicitation", may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2024. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2024table2 and http://solicitation.nasaprs.com/ROSES2024table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH24ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on C.8 Lunar Data Analysis Program (.pdf) to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read C.1 Planetary Science Research Program Overview (.pdf) from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the division overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2024 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at sara@nasa.gov, but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2024 blog feed for amendments, clarifications, and corrections to at https://science.nasa.gov/researchers/solicitations/roses-2024/, and (3) The ROSES-2024 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

The Nebraska SBIR/STTR Initiative provides financial assistance to small businesses in Nebraska participating in the federal SBIR/STTR programs. This state initiative offers Phase 0 assistance to help businesses apply for federal Phase 1 funding and matching funds for successful Phase 1 and Phase 2 federal awards. The initiative aims to promote innovation and technology transfer among small businesses in Nebraska, with a total fund availability of up to $6 million per year. Grant renewed every year. Grant Annual opening/closing deadline: July 1st to June 30th

The FY24 RCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. The Concept Award is not intended to support an incremental progression of an already established research project; instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not required. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of rare cancers or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i., Full Application Submission Type, for more information.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 RCRP prioritiesInnovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs, and other federal government agencies are highly encouraged.DOD FY24 Rare Cancers Concept Award 5These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.

The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a strong scientific rationale and study design. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.The following are important aspects of the EHDA: Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of the award mechanism. Although not all-inclusive, the following examples are ways in which the proposed research project may be innovative: Explores a novel idea and/or research question in TSC research and/or patient care. Uses or develops novel methods or technologies to address a question in TSC research and/or patient care. Applies or adapts existing methods or technologies for novel TSC research or clinical purposes that differ fundamentally from those originally intended.

The Woodruff Foundation provides funding to tax-exempt, nonprofit organizations located in Cuyahoga County, Ohio, aiming to enhance behavioral health. This initiative supports programs across several focus areas, including treatment, education and prevention, coordination of resources in the community, research, and advocacy. Past funded programs have covered a wide range of services, such as bereavement support, integrated care, guardianship services, and recovery support from addiction and substance abuse. To qualify for funding, organizations must comply with specific eligibility criteria, including being tax-exempt under section 501(c)(3) of the IRS code, serving in one of the foundation's focus areas, operating in Cuyahoga County, and having submitted reports on any previous grants. Grant renewed every year. Grant Annual Winter opening/closing deadline: November 15th to December 15th

The CTRA supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC. Projects supported by this award mechanism may include, but are not limited to: Studies moving from preclinical to clinical research and/or the reverse; or analyzing human anatomical substances and/or data associated with completed clinical trials to understand the mechanism of action, or to improve diagnosis, prognosis, or treatment. Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/pharmacodynamics. Pilot clinical trials, where limited clinical testing (e.g., small sample size) of a novel intervention to produce information on diagnostic or therapeutic effectiveness, safety, tolerability, or mechanisms of action. These studies should be aimed at obtaining preliminary data leading to the development of interventions with the potential to improve TSC outcomes. New Studies improving clinical care of TSC encompassing the analysis of existing real-world clinical practice data to develop/improve guidelines for better outcomes in defined areas relevant to the FY24 TSCRP focus areas, include but are not limited to epilepsy surgery, tumor resection, reproductive health, perinatal surveillance and care, etc.Preclinical studies may be appropriate but must include a clinical component. Projects that are strictly animal research will not be considered for CTRA funding and should consider other FY24 TSCRP funding opportunities.

The FY23-24 Drone Replacement Program is funded by the Florida Department of Law Enforcement (FDLE) to assist agencies in replacing non-compliant drones with those from approved manufacturers. The program was established following the 2022 amendment of Section 934.50, Florida Statutes, mandating agencies using non-compliant drones to replace them by specific deadlines. Eligible agencies will receive funds based on the initial purchase price and total flight hours of the non-compliant drones, following a detailed depreciation schedule. Recipients are required to relinquish the non-compliant drones in working condition to FDLE, which will then be analyzed by the Florida Center for Cybersecurity at the University of South Florida. Criminal Justice Information Data Security: Acceptance of this award, constitutes understanding that transmission of Criminal Justice Information (CJI) between locations must be encrypted to conform to the Federal Bureau of Investigation (FBI) Criminal Justice Information Services (CJIS) Security Policy.

The IDA promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale. The following are important aspects of the IDA: Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care. Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (to the next logical step) is not considered innovative. Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, and/or data from the published literature that are relevant to TSC and the proposed research project, are required. New-to-the-Field Investigator (NFI): The FY24 TSCRP IDA mechanism encourages applications from investigators in the early stages of their TSC research career. The NFI Option is designed to support the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into TSC research. Applications to the NFI Option will compete separately from Established Investigators submitting to the regular IDA. PIs applying under the NFI category are strongly encouraged to strengthen their applications through collaboration with investigators experienced in TSC research and/or possessing other relevant expertise as demonstrated by a record of funding and publications. See Attachment 8: Eligibility Statement.

The "DoD Multiple Sclerosis, Early Investigator Research Award" is a grant designed to support early-stage researchers in developing a Multiple Sclerosis-focused research project under the guidance of experienced mentors, with the aim of advancing their careers and contributing to the understanding and treatment of Multiple Sclerosis.

This funding opportunity supports innovative bioscience research projects in Delaware that have the potential for significant economic impact, targeting researchers and businesses in the developmental stage.

EPoC – Entrepreneurial Proof of Concept o Supports proof of concept research towards establishing a new Delaware-based business by the end of the grant period. o Up to $75,000 for 1 year . Proposal must be submitted as a single electronic PDF document at the link provided on the CAT website https://cat.dbi.udel.edu. Please note that submission and award processes have changed.Proposal must be submitted as a single electronic PDF document at the link provided on the CAT website https://cat.dbi.udel.edu. Please note that submission and award processes have changed.

This funding opportunity supports collaborative bioscience research projects between Delaware academic institutions and businesses, aimed at fostering innovation and economic growth in the state.

The FY24 RCRP RCDA supports the development of clinical or preclinical data sets and research resources that advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Major gaps in patient care of rare cancers include lack of communication and dissemination strategies for rare cancers research and clinical findings within communities; lack of therapeutics and mechanistic studies to inform treatment development; lack of research and clinical resources, including patient tissues, cell, and tumor models; and lack of infrastructure for sharing data and other resources.The intent of this funding opportunity is to develop research platforms that can share resources and knowledge pertaining to available preclinical or clinical research models, molecular pathways, and therapeutic approaches to facilitate collaboration and information sharing among stakeholders such as researchers, patients, caregivers, clinicians, and other members of the rare cancers community.Clinical or preclinical datasets should strive to integrate or develop the following research resources. This list is not all-inclusive: Building and sharing rare tumor biospecimen repository with clinical annotation Databases/banks for centralizing and sharing data for patient registries that can be accessed globally Centralizing and sharing research models and molecular data related to genomics/ transcriptomics/immune profiling/proteomics/metabolomics/methylomics/bioinformatics Generating a data/reagent/model exchange program where researchers can list resources that they are willing to share and are tagged with indications that may be relevant Platform to enable or leverage longitudinal studies of disease natural history and treatment response Development of novel methods and systems for collection, sharing, and analysis of data or biospecimensApplicants should include a well-formulated project design based on a strong scientific rationale and clearly articulate how the proposed resource platform or community development addresses an unmet need in rare cancers research. Applicants should explain the advantage of their approach to developing resources or community versus standard methodologies, techniques, or scopes. A clear plan for collaboration and data sharing needs to be demonstrated. It is critical to demonstrate how the outcome of the proposed project can benefit type(s) or sub-type(s) of rare cancers. It is encouraged for the research platform/resource to have an effect on multiple types or sub-types of rare cancers.Key Elements of the Resource and Community Development Award are as follows: Impact: Outcomes of the RCDA must have potential for major impact on an unmet need in rare cancers research. A resource, as developed in the proposed research, should aim forDOD FY24 Rare Cancers Resource and Community Development Award 5long-term anticipated advantages toward greatly improving outcomes for people with rare cancers. Patient Advocate Partnership: Applications to the RCDA funding opportunity are required to include patient advocates who are involved with patient advocacy organization(s). The research team must include at least two rare cancers patient advocates who will be early and integral partners throughout the planning and implementation of the research project. Patient advocates should be involved in the development of the research question, project design, oversight, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, and not limited to attending seminars and semi-annual meetings. The patient advocates must be individuals who have been directly impacted by a rare cancer either by being diagnosed themselves or as a caretaker/family member of a patient, and they should be active in a cancer advocacy organization or within a support group focused on their rare cancer. Their role should be focused on providing objective input on the research and its potential impact for individuals with or at risk for a rare cancer. The patient advocates should have a high level of understanding of current rare cancers research. Preliminary Data: Due to the developmental nature of this award, preliminary data are not required but may be included, if available, to address the feasibility of the resource to be developed. Whether or not preliminary data are included, applications must apply solid scientific rationale and logical reasoning based on existing knowledge to the development of the proposed product. Clinical Research: Research involving human subject use is permitted under this mechanism but is restricted to studies without clinical trials. Clinical trials will not be supported. Applications focused on clinical research should demonstrate how the study will leverage clinical information to address knowledge gaps in the development of platforms that can be utilized for sharing data and tissue, the development of clinical annotation datasets, process development, and/or infrastructure development. Applied Research: Preclinical studies utilizing or creating animal models to further research into rare cancers may be supported by this funding opportunity. The RCDA is intended to support projects that will have the potential to move beyond the realm of basic research, with results that may impact clinical research or patient outcomes. Community Building: A plan describing how the rare cancers stakeholder community will be built/enhanced and the communitys involvement with developing the resource platform is required. It is also important to justify how the community is essential for the development and sustainment of the resource platform. Dissemination: A Dissemination Plan is required. The plan should describe the means by which the fully developed resource platform will be made easily available to the scientific and/or clinical community. Dissemination of resource platform will play a major role by not only educating the rare cancer community about the recent progress, but also help to develop an informational network.DOD FY24 Rare Cancers Resource and Community Development Award 6 Sustainment: A plan that outlines the sustainability of the resource in the future is required. The plan should detail the types of rare cancers that are less studied in the collaborations and the resources to be gathered, annotated, and sustained. Additional expansion and feasibility plans should be included. It is important to demonstrate how the outcomes of the current award will be continued and eventually will help the rare care cancer community, beyond the award period.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 RCRP priorities.Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for women's health.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.